# CLIO-8421

Source: https://onco.cc/drugs/clio-8421/  
OnCo record `clio-8421` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CLIO-8421 is an experimental dual-payload antibody-drug conjugate from Callio Therapeutics, in preclinical development for non-small cell lung cancer and metastatic breast cancer.

## Summary

CLIO-8421 is a dual-payload antibody-drug conjugate from Callio Therapeutics. A TROP2-directed dual-payload ADC; the company names only the target. Its furthest stage is preclinical development, for non-small cell lung cancer and metastatic breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. IND-enabling on the company pipeline chart. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: CLIO-8421
- Modality: Dual-payload antibody-drug conjugate
- Mechanism: A TROP2-directed dual-payload ADC; the company names only the target.

## Sources

- Callio Therapeutics: calliotx.com: https://calliotx.com/

## Connected records

- targets: [TROP2](https://onco.cc/targets/trop2/)
- companies: [Callio Therapeutics](https://onco.cc/companies/callio-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/clio-8421.json